Table: monthly_update_prescription_drugs_intro_to_the_market_excel , manufacturer_name like D*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Daiichi Sankyo, Inc.	65597080101	"DATROWAY® (datopotamab deruxtecan-dlnk) One 100 mg single-dose vial"	2025-01-27	4891.0700	None	1	19224	None	None	None	None	None	None	None	None
Deciphera Pharmaceuticals, LLC	73207030440	Romvimza (vimseltinib) Capsule, 30 mg 1 Carton (8 count blister in wallet)	2025-02-20	26128.0000	Marketing Plan in the U.S. - ROMVIMZA™ is a is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. For additional information about Romvimza, please see the full Prescribing Information at www.romvimza.com. Romvimza will be marketed to healthcare professionals (HCPs) by a team of field-based professionals and its expenditures will include spending on the following areas. Deciphera's marketing initiatives will focus on raising awareness of tenosynovial giant cell tumor "TGCT", and its potential treatment. Supporting the launch of Romvimza may include comprehensive education that will be provided by Deciphera's employees to HCPs about the approved indication, dosing and administration, mechanism of action (MOA), and the efficacy and safety data consistent with the FDA approved label. Deciphera will have available and provide to HCPs various printed materials, patient brochures as well as offer peer to peer educational programs (in-person and virtual) describing both the TGCT disease state and the FDA-approved clinical profile of Romvimza. Additional activities may include the development of websites, webcasts, and other digital media offerings. Deciphera will participate in scientific meetings and congresses that will be attended by HCPs and may engage with HCPs through such attendance. Pricing Plan in the U.S. - Romvimza is currently only approved in the U.S. Deciphera is committed to ensuring patient access and the price for Romvimza was set after doing extensive research and understanding the value of Romvimza relative to other available treatments, as well as the unmet medical need, and disease burden of tenosynovial giant cell tumor "TGCT". Deciphera’s research also entailed evaluating the competitive landscape and payer environment, as well as business operational continuation needs. Deciphera is committed to supporting TGCT patients and removing barriers to access. As part of that commitment, Deciphera has established Deciphera AccessPoint, a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	20	None	1	None	None	None	None	Currently, the exact population of tenosynovial giant cell tumor "TGCT" patients in the US is not clearly understood. It is estimated that there may be approximately 1,400 incident cases in the US annually. Romvimza may be used in a smaller subset of these patients per its label. The first sale of this package size occured on 2/20/2025.	None
Dr. Reddy's Laboratories, Inc.	43598060330	Dasatinib 100mg Tablet, 30	2025-03-04	4561.5800	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None
Dr. Reddy's Laboratories, Inc.	43598060430	Dasatinib 140mg Tablet, 30	2025-03-04	4561.5800	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None
Dr. Reddy's Laboratories, Inc.	43598059960	Dasatinib 20mg Tablet, 60	2025-03-04	2530.9400	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None
Dr. Reddy's Laboratories, Inc.	43598060060	Dasatinib 50mg Tablet, 60	2025-03-04	5061.8700	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None
Dr. Reddy's Laboratories, Inc.	43598060160	Dasatinib 70mg Tablet, 60	2025-03-04	5061.8700	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None
Dr. Reddy's Laboratories, Inc.	43598060230	Dasatinib 80mg Tablet, 30	2025-03-04	4561.5800	None	1	450000	None	None	None	None	None	None	1) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number of patients listed is based on the number of patients with leukemia in the US; 2) Product was not acquired; 3) The market introduction date is the date when the product was available for sale. For purchases of this product, the drug was not available for sale in California until this intro date. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting.	None